Related Experiment Video
Updated: May 29, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites
1Center of Infectious Diseases, West China Hospital of Sichuan University Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan Province, China.
Abstract:
Nucleos(t)ide analogs (NAs) have become the mainstream drugs for the treatment of chronic hepatitis B virus infection. Drug resistance to NAs, however, has posed a major obstacle in obtaining sustained viral suppression. Standardized definitions of terms and nomenclature in discussing NAs resistance have been proposed. Drug resistance to NAs is produced by a combination of viral, host and antiviral drug factors. A detailed understanding of the mechanisms and effects of mutation sites that cause resistance to NAs is important for the design of rational treatment and management of patients with existing drug resistance.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Viral Mutations
Treatment Resistant Cancers
Mechanism of Antibiotic Resistance in MRSA
Hepatitis
Drug toxicity: Idiosyncratic Reactions

